Corcept Therapeutics, Inc. (CORT)

[Thurly]

Corcept Therapeutics Announces Poster Presentations on Mifepristone
for the Treatment of Patients with Cushing’s Syndrome
at the 27th Annual American Association of Clinical Endocrinologists

Press Release delivered via email

MENLO PARK, Calif. (May 14, 2015) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that four posters about mifepristone will be presented at the 24th annual American Association of Clinical Endocrinologists (AACE) being held at the Music City Convention Center in Nashville, TN from May 13 – 17, 2015.
“We are pleased that physicians have taken a strong interest in mifepristone and its potential to treat patients with Cushing’s syndrome,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.

In addition to presentation of the four abstracts described below, AACE attendees will have the opportunity to attend a “Product Theatre” talk by Ty Carroll, M.D., whose topic will be “Not-So-Subclinical Cushing’s Syndrome.” Corcept is a sponsor of Dr. Carroll’s presentation.

Friday, May 15, 2015

Poster #131: “Resistant metabolic abnormalities prompting Cushing’s syndrome work-up and treatment with mifepristone”
Douglas Beatty, M.D., Rachel Bunta, Dat Nguyen, PharmD

Poster # 840: “Mifepristone re-established glycemic control in a Cushing’s syndrome patient that relapsed after a 21 month interruption”
Todd Frieze, M.D., James Smith, Ph. D.

Product Theater: “Not-So-Subclinical Cushing’s Syndrome”
Ty Carroll, M.D.

Saturday, May 16, 2015

Late-Breaking Poster: “Use of mifepristone in an ectopic Cushing’s syndrome patient pending tumor localization”
Adeela Ansari, M.D., Precious Lim, Ph.D., Dat Nguyen, PharmD

Late-Breaking Poster: “Improved response to octreotide LAR for ectopic Cushing’s syndrome during mifepristone therapy: A case study”
Andreas Moraitis, M.D., Richard Auchus, M.D.